Foghorn Therapeutics Inc. · NASDAQ:FHTX
Foghorn Therapeutics — Technical Presentation (April 2023)
14 slides from Foghorn Therapeutics's technical presentation, April 2023
Slide 1: Pre-clinical efficacy of targeting BAF complexes through inhibition of BRG1 and BRM by FHD-286 in AML
Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML Warren Fiskus, Jessica Piel, Murphy Hentemann, Christopher P. Mill, Christine E. Birdwell, Kaberi Das, John A. Davis, Tapan M. Kadia, Naval Daver, Sanam Loghavi,
Slide 2: Dual ATPases SMARCA4 (BRG1) and SMARCA2 as therapeutic targets in AML
Dual ATPases SMARCA4 (BRG1) and SMARCA2 as therapeutic targets in AML • SWI/SNF chromatin remodeling complexes regulate essential cellular processes, e.g., cell cycle progression, differentiation, and genome stability. • The mammalian SWI-SNF complexes are also known as BAF complexes. They are compo
Slide 3: CRISPR screen revealed SMARCA4 to be a dependency in AML cell lines
CRISPR screen revealed SMARCA4 to be a dependency in AML cell lines and expressed in patient-derived AML cells with MLL1r or mtNPM1 AML CRISPR dependency screen SMARCA4 log2(TPM+1) Expression (SMARCA4) A 9 B PD PD 8 SET2 mtNPM1 AML MLL1r AML MV411 1 2 3 4 1 2 3 4 TF1 HEL92.1.7 7 MOLM13 BRG1 KASUMI1
Slide 4: Treatment with FHD-286 induces differentiation followed by loss of viability
Treatment with FHD-286 induces differentiation followed by loss of viability in AML cells with MLL1r or mtNPM1 or 3q26 MECOM locus lesion A C E Day 14 (7 days post CD11b sort) * Dead cells % CD11b positive cells % CD11b-positive cells 50 80 AML191 OCI-AML3 AML194 * 40 MOLM13 60 * 30 40 * * 20 AML191
Slide 5: FHD286 treatment reduced H3K27Ac peaks at super-enhancer-driven genes
FHD286 treatment reduced ChIP-seq (H3K27Ac) peaks at super-enhancer-driven gene expressions and core transcription factor circuitry in AML cells with MLL1r A MOLM13 Control B MOLM13 Control C MOLM13 100 nM FHD-286 800000 H3K27Ac Signal at Enhancers LY86 (#1) Super-Enhancers: 1009 600000 CEBPA (#19)
Slide 6: FHD-286 induced mRNA perturbations and negative enrichment of c-Myc targets
FHD-286 induced mRNA perturbations and negative enrichment of mRNA of gene-sets including c-Myc targets in AML cells with MLL1r MOLM13 C A 100 nM FHD-286/Control 350 MOLM13 FHD-286/Control MYC MPO LYZ IRF8 GATA2 XBP1 HALLMARK_MYC_TARGETS_V1 300 SPI1 MEF2D 250 IL7R MS4A3 -log10 p-value 0.0 CD180 HEXI
Slide 7: Concordantly perturbed chromatin accessibility (ATAC-Seq) and mRNA expressions (RNA-Seq)
Concordantly perturbed chromatin accessibility (ATAC-Seq) and mRNA expressions (RNA-Seq) due to FHD-286 treatment in AML cells with MLL1r A B MOLM13 MOLM13 100 nM FHD-286, 16 hrs/Control 100 nM FHD-286/Control TNFRSF4 XBP1 GATA2 HEXIM1 FBXO32 BBC3/PUMA HDAC6 BRD2 KAT5 JARID2 CDK6 EZH2 RXRA LAMP5 DPY
Slide 8: FHD-286 treatment reduced MEPs (sc-RNA-Seq) with perturbations in mRNA gene-sets
FHD-286 treatment reduced MEPs (sc-RNA-Seq) with perturbations in mRNA gene-sets PD MLL-AF9 AML A C 100 nM FHD/Control HALLMARK_HEME_METABOLISM HALLMARK_OXIDATIVE_PHOSPHORYLATION HALLMARK_TGF_BETA_SIGNALING HALLMARK_WNT_BETA_CATENIN_SIGNALING HALLMARK_PI3K_AKT_MTOR_SIGNALING HALLMARK_APOPTOSIS HALLM
Slide 9: FHD-286 reduced protein expression of c-Myc, CDK6, BCL2 and PU.1 in AML LSCs
FHD-286 treatment reduced protein expressions of c-Myc, CDK6, BCL2 and PU.1 with upregulation of p-H2AX, cleaved PARP and Caspase-3 in phenotypically defined AML LSCs A PD, MLL-AF6 + mtNRAS AML PD, mtNF1, mtBCOR, mtBCORL1, B C MOLM13 mtFLT3 AML#17 MOLM13 100 nM FHD286, 48 hrs/Control 100 nM FHD-286
Slide 10: Co-treatment with FHD-286 and decitabine, venetoclax or BETi synergistically induces loss of viability
Co-treatment with FHD-286 and decitabine, venetoclax or BETi synergistically induces in vitro loss of viability in AML cells with MLL1r or mtNPM1 A MV4-11 C MV4-11 E MV4-11 80 60 50 50 50 Delta Synergy Score (ZIP) Delta Synergy Score (ZIP) Delta Synergy Score (ZIP) 38.35 37.84 36.48 39.89 52.42 54.4
Slide 11: FHD-286 reduces in vivo leukemia initiating potential of mtNPM1 + FLT3-ITD AML PDX
Treatment with FHD-286 significantly reduces in vivo leukemia initiating potential of a mtNPM1 + FLT3-ITD AML PDX A AML Burden of ex vivo-treated B Re-transplant:Leukemia Burden mtNPM1 + FLT3-ITD + FLT3-TKD Luc/GFP PDX mtNPM1 + FLT3-ITD + FLT3-TKD Luc/GFP AML PDX after 5 weeks of earlier Rx leukemia
Slide 12: Superior in vivo efficacy of FHD-286 combinations in PDX model of MLL1r AML
Superior in vivo efficacy following treatment with FHD-286-based combination with decitabine, venetoclax or BETi in PDX model of AML with MLL1r A B MLL-AF9 + FLT3-TKD Luc/GFP PDX AML Burden of 6 weeks Rx MLL-AF9 + FLT3-TKD PDX Luc/GFP Vehicle (n=7) ✱✱✱ 100 1.5 mg/kg FHD-286 (n=7) % Survival Vehicle
Slide 13: Conclusions and Future Directions
Conclusions and Future Directions • Treatment with FHD-286 overcomes differentiation block and induced differentiation in AML cells with MLL-r, mtNPM1 and chromosome 3q26 lesions. • FHD-286 negatively enriched gene-sets of MYC and E2F targets, inflammatory response and IL6-JAK- STAT3 signaling, whil
Slide 14: Acknowledgments
Acknowledgments Dr. Bhalla’s Lab Collaborators MDACC: Christopher Mill, PhD Naval Daver, MD Courtney DiNardo, MD Tapan Kadia, MD Christine Birdwell, PhD Koichi Takahashi, MD Kaberi Das, PhD Ghasan Issa, MD John Davis, BS Sherry Pierce, PhD Hanxi Hou, BS Xiaoping Su, PhD Sanam Loghavi, MD Foghorn The
Foghorn Therapeutics — Technical Presentation (April 2023) on 6ix